International Journal of Health Technology and Innovation
An Official Journal of **Kalam Institute of Health Technology** | ISSN - **2583-8547**

EDITORIAL

# Biosimilars and Biologicals: Transforming the Healthcare Landscape

Shashi Bala Singh

*Emeritus Scientist, Indian Council of Medical Research Former DG (Life Sciences) DRDO & Director NIPER, Hyderabad*

***Received: 10th January , 2026; Revised: 15th February, 2026; Accepted: 09th March, 2026; Available Online: 04th April, 2026***

International Journal of Health Technology and Innovation (2026)

**How to cite this article:** Singh SB. Biosimilars and Biologicals: Transforming the Healthcare Landscape. International Journal of Health Technology and Innovation. 2026;5(1):1-2.

**Doi:** 10.60142/ijhti.v5i01.01

**Source of support:** Nil.

**Conflict of interest:** None

## INTRODUCTION

In today's healthcare environment, where escalating costs and the growing prevalence of chronic illnesses place immense pressure on systems worldwide, biological medicines have emerged as transformative therapies. These complex products, derived from living organisms through advanced biotechnological processes, have dramatically improved outcomes for patients with cancer, rheumatoid arthritis, diabetes, multiple sclerosis, and rare genetic disorders. Unlike conventional small-molecule drugs, biologics are large, intricate molecules—often proteins or antibodies—making them exceptionally effective but also extremely expensive to develop, manufacture, and supply.

High prices have historically restricted access, particularly in low- and middle-income countries, exacerbating health inequities. Biosimilars address this challenge directly. Defined by the World Health Organization (WHO) as biological products that are highly similar to an already licensed reference biologic (the originator), biosimilars show no clinically meaningful differences in terms of quality, safety, or efficacy. This determination relies on a rigorous, stepwise comparability exercise and a totality-of-evidence approach, encompassing extensive analytical characterization, non-clinical studies, and—where necessary—clinical data.[1]

By 2026, biosimilars have evolved far beyond being mere "copies." They represent a fundamental structural change in pharmaceutical markets, healthcare policy, and resource allocation. They foster competition, drive down prices, expand patient access, and support the long-term financial sustainability of health systems.

### The Dawn of a Competitive Era

The economic impact of biologics is profound. In the United States, these therapies constitute only about 5% of all prescriptions but consume nearly 51% of total drug expenditure [2]. This disproportionate spending has prompted intense scrutiny from payers, governments, and policymakers, who increasingly view biosimilar competition as a vital cost-control mechanism.

Since the first biosimilar approvals in the U.S. in 2015, the cumulative savings have been remarkable: an estimated $56.2 billion through 2024, with $20.2 billion saved in 2024 alone. These savings have translated into approximately 3.3 billion additional days of patient therapy [3]. Yet uptake remains inconsistent. By late 2025, the FDA had approved 76 biosimilars, but market penetration in many key therapeutic areas stayed below 20% [2]. Approval alone does not guarantee utilization—barriers such as prescriber confidence, reimbursement structures, and commercial strategies continue to slow adoption.

Globally, biosimilars still trail originator products in volume, but the trajectory is strongly upward. Projections indicate the worldwide biosimilars market could reach around $75 billion by 2030, fuelled by patent expiries, new therapeutic indications, and supportive policies [4]. In the U.S. alone, more than 118 reference biologics are expected to lose exclusivity over the coming decade, unlocking a potential $234 billion in savings if robust competition develops [3]. This impending wave of patent cliffs—particularly for blockbuster monoclonal antibodies and oncology agents—promises intensified price competition and greater affordability for high-cost treatments.

### Regulatory Reforms: Catalysts for Efficiency and Innovation

Recent regulatory evolution has accelerated this momentum. In October 2025, the U.S. FDA launched initiatives to streamline biosimilar development and eliminate redundant requirements [2]. A November 2025 draft guidance further clarified that comparative clinical efficacy studies may be waived in many cases when robust analytical, functional, and pharmacokinetic/

*Author for Correspondence: drshashisingh@gmail.com

pharmacodynamic data provide strong evidence of similarity [5]. This "analytics-first" philosophy leverages decades of experience to lower development costs without sacrificing safety or efficacy standards.

Europe has followed a parallel path. The European Medicines Agency (EMA) has refined its "tailored clinical approach," reducing the scope of mandatory trials based on accumulated scientific knowledge [6]. Meanwhile, a December 2025 EU political agreement on pharmaceutical reform established a baseline of 8 years' data protection plus 1 year of market protection, with possible extensions under specific innovation conditions—striking a balance between rewarding R&D and enabling timely biosimilar entry [7].

India, a major player in affordable medicines, continues to modernize its framework. In May 2025, the Central Drugs Standard Control Organization (CDSCO) issued draft revised Guidelines on Similar Biologics, emphasizing advanced orthogonal analytical methods, in-vitro functional assessments, and closer alignment with WHO standards (TRS 1043) [8]. These global reforms reflect growing regulatory convergence, prioritizing scientific rigor, efficiency, and patient-centric outcomes.

**Empowering Patients and Strengthening Health Systems**

The core value of biosimilars lies in real-world patient benefit. Approved products are expected to match their reference biologics in safety, purity, potency, and clinical performance, with no meaningful differences [1,6]. Robust post-marketing surveillance, immunogenicity monitoring, and product traceability ensure ongoing safety.

Adoption trends are encouraging. Across OECD nations, biosimilars' market volume share rose from roughly 11% in 2019 to 22% in 2023 [9]. In markets with competitive tendering or procurement, price reductions frequently exceed 50%, and in some European cases reach 80% for mature molecules [9]. Such savings allow health systems to treat more patients and reallocate funds toward novel therapies.

Challenges remain, however. Physician and patient skepticism, aggressive originator commercial tactics, prolonged patent litigation, and misaligned incentives can hinder uptake. Overcoming these requires sustained education, transparent data sharing, swift patent resolution, and policy designs that reward competition.

**India's Union Budget 2026–27: A Strategic Leap Forward**

The Union Budget 2026–27, presented on 1 February 2026, positions India as an emerging biopharma leader. The flagship BioPharma SHAKTI initiative commits ₹10,000 crore over five years to build world-class manufacturing and innovation capacity in biologics and biosimilars [10].

Supporting measures include establishing three new National Institutes of Pharmaceutical Education and Research (NIPERs) and upgrading seven existing ones to bolster expertise in biosimilar science and regulatory affairs. A network of over 1,000 accredited clinical trial sites will speed high-quality research, while CDSCO gains a dedicated scientific cadre for faster, more predictable approvals [10].

Customs duty exemptions on 17 critical drugs—including oncology and rare-disease therapies—will lower import costs and improve access. Broader health investments in infrastructure, workforce, and institutions align with long-term public health objectives [10].

Industry observers view these steps as transformative, helping India transition from a generics powerhouse to a global force in high-value biopharmaceuticals, including biosimilars and advanced therapies.

**Vision for the Future**

As patent expiries accelerate and regulatory pathways mature, biosimilars stand ready to reshape healthcare economics. Achieving projected multi-billion-dollar savings demands coordinated policies, clinician buy-in, patient education, and vigilant pharmacovigilance. Far from mere substitutes, biosimilars serve as powerful tools for health equity, system resilience, and sustainable innovation—freeing resources for next-generation breakthroughs while broadening access to life-changing treatments.

The way forward rests on evidence-based policymaking, international alignment, and collaborative stakeholder efforts to turn the full potential of biosimilars into tangible, widespread benefits for patients everywhere.

## REFERENCES

1. WHO TRS 1043, 2022.
2. FDA, Oct 2025
3. AAM Savings Report, 2025.
4. IQVIA, 2024.
5. FDA Draft Guidance, Nov 2025
6. EMA papers, 2025
7. EU Reform Agreement, Dec 2025.
8. CDSCO Draft Guidelines, 2025.
9. OECD, Feb 2025.
10. Union Budget 2026–27 announcements and industry analyses.